Guei-ying Chen
Ministry Of Health And Welfare, TPQ, Taiwan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan.
Journal: The Kaohsiung journal of medical sciences
Published: April 08, 2025
Real-world efficacy and safety of universal 8-week glecaprevir/pibrentasvir in patients with chronic hepatitis C with early chronic kidney disease or pre-end-stage renal disease: Insights from a nationwide hepatisis C virus registry in Taiwan.
Journal: The Kaohsiung journal of medical sciences
Published: October 27, 2024
Impact of HCV eradication by directly acting antivirals on glycemic indices in chronic hepatitis C patients -a nationwide Taiwan HCV registry.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: April 23, 2024
Benefits of Hepatitis C Viral Eradication: A Real-World Nationwide Cohort Study in Taiwan.
Journal: Digestive diseases and sciences
Published: April 02, 2024
Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan.
Journal: Infectious diseases and therapy
Published: January 27, 2024
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program.
Journal: Clinical and molecular hepatology
Published: August 02, 2023
Effectiveness and safety of 8-week glecaprevir/pibrentasvir in HCV treatment-naïve patients with compensated cirrhosis: real-world experience from Taiwan nationwide HCV registry.
Journal: Hepatology international
Published: October 28, 2022
Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals.
Journal: Viruses
Published: December 26, 2021
Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan.
Journal: Infectious diseases and therapy
Published: October 23, 2021
Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan.
Journal: Scientific reports
Published: September 07, 2021
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan.
Journal: Journal of the Formosan Medical Association = Taiwan yi zhi
Published: August 20, 2021
Last Updated: 09/26/2026